{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 39,
  "pageCount": 197,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "This slide is used by an activist investor to frame the CEO transition as a point of investor concern.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "headshot",
    "bullet_list",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/39",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.16,
        "x": 0.11,
        "y": 0.605
      },
      "kind": "callout",
      "text": "Appointed CEO of Bristol-Myers on January 20, 2015. Effective May 5, 2015",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be411af5-97fa-49c1-bdd0-252b5a52f295",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe investors were disappointed to see the CEO transition, as Andreotti helped transform the pharmaceutical company into an immunotherapy pioneer, but were hopeful for continued success",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0936-7173-ab2e-b5b86c8bd314",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.16,
        "x": 0.11,
        "y": 0.325
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cecf8e1a-77b7-43a3-900d-80175352aaec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.295,
        "y": 0.325
      },
      "kind": "list",
      "text": "Dr. Caforio began his career in Medical Affairs at Abbott Laboratories. He joined Bristol-Myers in 2000 as Vice President and General Manager, Italy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4ff1503-7abd-4bc5-acc8-67cf23a24b49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.295,
        "y": 0.46
      },
      "kind": "list",
      "text": "2004-2007: SVP, European Marketing and Brand Commercialization; 2007-2009: SVP, US Oncology; 2009-2010: SVP, Oncology, US and Global Commercialization; 2010-2011: SVP, Global Commercialization and Immunology; 2011-2013: President, US; 2013-2014: EVP & CCO; 2014-2015: COO",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d643febc-e0ff-41fb-950e-029999a76726",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.855
      },
      "kind": "paragraph",
      "text": "We believe investors were disappointed to see the CEO transition, as Andreotti helped transform the pharmaceutical company into an immunotherapy pioneer, but were hopeful for continued success",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc99ecc3-9881-4733-a861-1fc3db17ccf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Following years of success and share price outperformance, Bristol-Myers made a CEO change.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5dafb1d-38dd-40d7-81ac-b8d3074279d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Public company filings.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4bf1af6-37be-4456-bfb7-c0c14c15108c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "In 2015, Giovanni Caforio Became Bristol-Myers' CEO, Succeeding Lamberto Andreotti",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "849eb1e3-376e-4f9e-97aa-22559f84f94a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}